Journal of Ophthalmology / 2020 / Article / Tab 5

Research Article

Effectiveness of Intravitreal Ranibizumab in Nonvitrectomized and Vitrectomized Eyes with Diabetic Macular Edema: A Two-Year Retrospective Analysis

Table 5

Comparison of the effect of intravitreal ranibizumab on BCVA, CMT, and TMV values in nonvitrectomized and vitrectomized eyes.

F value valuePartial eta2

BCVA (logMAR)
Main effect of time8.9990.00040.257
Main effect of time-group interaction2.3190.1080.082
Main effect of group1.2830.2680.047

CMT (μm)
Main effect of time9.419<0.00010.266
Main effect of time-group interaction1.9630.1270.070
Main effect of group0.4580.5050.017

TMV (mm3)
Main effect of time11.420<0.00010.305
Main effect of time-group interaction0.4290.6850.016
Main effect of group0.1380.7140.005

BCVA indicates best-corrected visual acuity; CMT, central macular thickness; TMV, total macular volume. Mixed-design ANOVA with one within-subject factor (time: 5 levels) and one between-subject factor (group: 2 levels). The main effect of time on BCVA (F(2.032, 52.827) = 8.999,  = 0.0004, partial eta2 = 0.257), CMT (F(2.973, 77.295) = 9.419, , partial eta2 = 0.266), and TMV (F(2.345, 60.957) = 11.420, , partial eta2 = 0.305) was statistically significant. The main effect of time-group interaction and the group was not statistically significant (all values >0.05, Table 5). A post hoc pairwise comparison showed a significant improvement in BCVA values from baseline to the 18th and 24th months of treatment ( and , respectively). There was a significant reduction in CMT values from baseline to the 12th, 18th, and 24th months of treatment (, , and , respectively). The reduction in TMV values was significant from baseline to the 6th, 12th, 18th, and 24th months of treatment (, , , and , respectively). All other pairwise comparisons for BCVA, CMT, and TMV values were not statistically significant.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.